Stimulation of Tregs by these fetal-like FOLR2+ TAMs is anticipated to be abrogated by anti-CTLA4 therapy, with CD86 instead able act as co-stimulation for the activation of naïve T cells and a subsequently enhanced anti-tumor response (Figure 2). This evidence concerns the gene FOLR2 and neoplasm.